MET and hepatocellular carcinoma: For example, research in hepatocellular carcinoma (43), in Chordoma (44), and in Colon Cancer (45) etc. Unlike in cancer patients, we observed decreased expression of MET in patients with AF by bioinformatic analysis, whereas MET is often overexpressed in cancer patients.